Abstract 195P
Background
Cervical cancer (CC) is one of the most preventable cancers among women due to the existence of human papillomavirus (HPV) vaccine. HPV vaccines reduce cervical cancer risk and protect against other HPV-associated cancers.
Methods
This a survey-based cross-sectional study that aims to evaluate the level of knowledge about HPV infection, CC and vaccine among Omani females. The survey was constructed from the NCI-HINTS survey after permission. The Arabic version of the survey was piloted and validated with good reliability score. The survey was distributed as a link in different social media platforms between August 2020- December 2020. There were 468 female participants from different regions of the Sultanate of Oman.
Results
Approximately 45% of the participants were 30-39 years old. The majority of participants (65.9%) were not aware about the need for Pap smear every three years as a screening for CC. Most of the participating females (88.4%) were willing to have Pap smears every three years if their health care provider recommended it. Few participants (22%) had heard about HPV. Most of the participants have never been examined or are aware if they have HPV infection. Almost all participants (93.8%) believe that HPV infection necessitates medical treatment. About a third (38.7%) are aware that HPV infection can cause cervical cancer and 60% females know that HPV can cause abnormal Pap smears. The vast majority (87%) of the participants have not heard of HPV vaccine as a preventive measure from CC. This study showed a significant association between age and the level of knowledge about the recent changes in the guidelines related to CC screening (p<0.05). It also demonstrates that there is no correlation between accepting to give their daughter the vaccine and their awareness of CC. Additionally, there was no significant association between age and their acceptance of doing Pap smear or their knowledge about HPV vaccine, but there is a significant correlation between age and the willingness to give the vaccine to their daughters (p<0.05).
Conclusions
Among Omani females of different age groups, there is a lack of knowledge regarding CC. In these contexts, efforts to promote HPV vaccination for cancer prevention remain critical.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
150P - Use of neoadjuvant chemotherapy for non-metastatic muscle-invasive bladder cancer in Asia-Pacific
Presenter: Ravindran Kanesvaran
Session: Poster viewing 03
Resources:
Abstract
Slides
151P - Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer: Real-world analysis of chemotherapy use and impact on patient outcomes
Presenter: Alison Hiong
Session: Poster viewing 03
152P - An epidemiologic study on PD-L1 expression with clinical observation of initial treatment pattern in the Chinese muscle invasive urothelial bladder carcinoma patients
Presenter: Liqun Zhou
Session: Poster viewing 03
153P - Efficacy and toxicity of HER2-targeted antibody-drug conjugates (ADCs) in the treatment of metastatic urothelial cancer (mUC): A systematic review
Presenter: Tiago Padua
Session: Poster viewing 03
154P - Can urine cytology predict variants of bladder cancer?
Presenter: Hikaru Mikami
Session: Poster viewing 03
155P - Search for circulating tumor cells in patients with urothelial cancer
Presenter: Irina Kruglova
Session: Poster viewing 03
156P - The association between response to enfortumab vedotin therapy and primary tumor location in Japanese urothelial carcinoma patients
Presenter: Nozomi Hayakawa
Session: Poster viewing 03
163P - Outcomes and toxicity of fosfesterol in metastatic castration-resistant prostate cancer: Experience from a low middle income country
Presenter: Manuprasad Avaronnan
Session: Poster viewing 03
164P - F-18 PSMA-PET/CT-guided percutaneous prostate biopsy
Presenter: Rajender Kumar
Session: Poster viewing 03
165P - Real-world utilisation of upfront chemohormonal therapy in metastatic hormone-sensitive prostate cancer
Presenter: Richard Kelly
Session: Poster viewing 03